Effect of a SGLT2 inhibitor on the systemic and intrarenal renin–angiotensin system in subtotally nephrectomized rats

• Published in: Journal of pharmacological sciences Vol. 137; no. 2; pp. 220 - 223
• Main Authors: Li, Lei, Konishi, Yoshio, Morikawa, Takashi, Zhang, Yifan, Kitabayashi, Chizuko, Kobara, Hideki, Masaki, Tsutomu, Nakano, Daisuke, Hitomi, Hirofumi, Kobori, Hiroyuki, Nishiyama, Akira
• Format: Journal Article
• Language: English
• Published: Japan Elsevier B.V 01.06.2018; Elsevier
• Subjects: Chronic kidney disease (CKD); Renin–angiotensin system (RAS); SGLT2 inhibitor; Renin–angiotensin system (RAS); SGLT2 inhibitor; Chronic kidney disease (CKD)
• ISSN: 1347-8613; 1347-8648; 1347-8648
• DOI: 10.1016/j.jphs.2017.10.006

We aimed to examine the effects of a sodium glucose co-transporter 2 (SGLT2) inhibitor on systemic and intrarenal renin–angiotensin system (RAS) in subtotally nephrectomized non-diabetic rats, a model of chronic kidney disease (CKD). Oral administration of the selective SGLT2 inhibitor, TA-1887 (10 mg/kg/day), for 10 weeks induced glycosuria. However, plasma renin activity, plasma angiotensinogen levels, kidney angiotensin II contents and renal injury were not significantly affected by TA-1887. These data indicate that chronic treatment with an SGLT2 inhibitor does not activate the systemic and intrarenal RAS in subjects with non-diabetic CKD.